Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]

Anónimo. FDA rules Novo Nordisk’s diabetes drug reduces risk of heart attack, stroke, cardiovascular death. DIA Daily 2017:2. [Ref.ID 102035]

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]

Messerli FH, Bangalore S, Rimoldi S, Gasowski J, Nussberger J. Are ACE inhibitors acceptable ingredients in polypills?. Lancet 2017;390:26. [Ref.ID 101670]

Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017;177:966. [Ref.ID 101591]

Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177:955-65. [Ref.ID 101590]

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]

Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S-J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. The American Journal of Gastroenterology 2017;112:1084-93. [Ref.ID 101543]

Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol 2017;73:487-97. [Ref.ID 101517]

Sondergaard KB, Weeke P, Wissenberg M, Olsen A-MS, Fosbol EL, Lippert FK, Torp-Pedersen C, Gislason GH, Folke F. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study. Eur Heart J 2017;3:100-7. [Ref.ID 101478]

Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]

McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]

Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017;356:j4. [Ref.ID 101389]

Anónimo. Celecoxib safety revisited. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:159. [Ref.ID 101041]

Zong G, Li Y, Wanders AJ, Alssema M, Zock PL, Willett WC, Hu FB, Sun Q. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. BMJ 2016;355:i5796. [Ref.ID 100999]

US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA 2016;316:1997-2007. [Ref.ID 100998]

Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008-24. [Ref.ID 100989]

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]

Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]